Dapagliflozin Targets Exercise Pressure and Heart Metabolism in HFpEF Trial
Mayo Clinic tests whether 6 months of the SGLT2 inhibitor dapagliflozin can reduce exercise-induced cardiac pressure in preserved-ejection-fraction heart failure.
Summary
Heart failure with preserved ejection fraction (HFpEF) is one of the hardest cardiac conditions to treat — patients have a normal pumping function but still suffer debilitating breathlessness, largely because pressures inside the heart spike abnormally during exercise. This Phase 2 trial from Mayo Clinic tested whether dapagliflozin, an SGLT2 inhibitor originally developed for diabetes, could lower those exercise-induced pressures and improve how the heart uses energy over six months. Participants were randomized to dapagliflozin or placebo. The primary outcome was pulmonary capillary wedge pressure during exercise — a direct measure of cardiac congestion — alongside assessments of cardiac metabolism. Results have not been published in the abstract, but the trial is completed, making its forthcoming findings highly anticipated for a condition with few proven therapies.
Detailed Summary
Heart failure with preserved ejection fraction accounts for roughly half of all heart failure cases and disproportionately affects older adults, women, and people with metabolic syndrome. Unlike heart failure with reduced ejection fraction, HFpEF has responded poorly to most pharmacological therapies tested to date, leaving clinicians with limited options and patients with persistently poor quality of life. Any agent that can meaningfully reduce cardiac congestion or improve energy metabolism in this population represents a major clinical advance.
This completed Phase 2 randomized controlled trial from the Mayo Clinic investigated dapagliflozin — a sodium-glucose cotransporter-2 (SGLT2) inhibitor — in patients with HFpEF over a six-month treatment period. Participants received either dapagliflozin or placebo. The primary endpoint was pulmonary capillary wedge pressure (PCWP) measured during exercise, which is a hemodynamically precise marker of left-heart filling pressure and congestion. Secondary goals included evaluation of cardiac metabolic changes, probing whether the drug's known effects on substrate utilization translate to the failing heart.
SGLT2 inhibitors have already demonstrated mortality and hospitalization benefits in heart failure with reduced ejection fraction, and observational and mechanistic data suggest they shift cardiac fuel use from glucose toward ketones and fatty acids — a potentially favorable metabolic switch in HFpEF. This trial directly tests that hypothesis with invasive hemodynamic measurements, providing mechanistic rigor beyond symptom-based endpoints.
Full results have not yet been published, limiting conclusions at this stage. However, the completed status signals that data analysis is underway or complete, and peer-reviewed publication is anticipated. If dapagliflozin lowers exercise PCWP, it would offer both mechanistic confirmation and a clinically meaningful target for this underserved population.
Caveats include the Phase 2 scale, which is designed for signal detection rather than definitive efficacy, and the abstract-only information currently available. Broader generalizability will depend on the enrolled population's characteristics.
Key Findings
- Trial tests dapagliflozin's ability to lower exercise-induced cardiac filling pressure in HFpEF over 6 months.
- Pulmonary capillary wedge pressure during exercise serves as the primary hemodynamic endpoint.
- Cardiac metabolism is a secondary target, probing SGLT2 inhibitor effects on heart fuel use.
- Phase 2 design at Mayo Clinic focuses on mechanistic signal detection, not large-scale efficacy.
- HFpEF has few proven therapies; a positive result could shift standard-of-care thinking.
Methodology
This is a completed Phase 2 randomized, placebo-controlled trial conducted at Mayo Clinic. Patients with HFpEF received dapagliflozin or placebo for 6 months, with invasive hemodynamic assessment of pulmonary capillary wedge pressure during exercise as the primary outcome. Cardiac metabolic parameters were also evaluated as secondary endpoints.
Study Limitations
Summary is based on the abstract only; full methodology, participant characteristics, and results are not yet available. The Phase 2 design is powered for signal detection rather than definitive efficacy conclusions. Generalizability cannot be assessed without knowing enrollment criteria and baseline demographics.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: